Oldhamianoside II inhibits prostate cancer progression via regulation of EMT and the Wnt/β‑catenin signaling pathway

Li,Kaizhi; Zhan,Xuemei; Sun,Jingyong; Wang,Tianfeng; Dong,Hongyan; Jing,Fanbo; Li,Dongmei; Cao,Yu; Liu,Yali; Wang,Lin; Li,Shengnan

doi:10.3892/ol.2018.8450

Oldhamianoside II inhibits prostate cancer progression via regulation of EMT and the Wnt/β‑catenin signaling pathway

Authors:
- Kaizhi Li
- Xuemei Zhan
- Jingyong Sun
- Tianfeng Wang
- Hongyan Dong
- Fanbo Jing
- Dongmei Li
- Yu Cao
- Yali Liu
- Lin Wang
- Shengnan Li
View Affiliations

Affiliations: Department of Pathology, Affiliated Hospital of Jining Medical University, Jining, Shandong 272029, P.R. China, Department of Pathology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Pharmacology, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China, Department of Hepatobiliary Surgery, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China, Department of Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Shandong Medical Biotechnological Center, Key Laboratory for Rare and Uncommon Diseases of Shandong Province, Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China, Department of Pharmacy, The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
Published online on: April 10, 2018 https://doi.org/10.3892/ol.2018.8450
Pages: 9457-9463

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oldhamianoside II is a novel triterpenoidsaponin that can be isolated from the roots of Gypsophila oldhamiana. In vitro and in vivo experiments have revealed that it inhibits tumor growth and metastasis in various types of tumor; however, the exact mechanism remains to be fully elucidated. In the present study, oldhamianoside II treatment in prostate cancer cells exerted substantial anticancer activity, including decreased cell proliferation and invasion. Mechanistically, oldhamianoside II was found to reverse the epithelial‑mesenchymal transition (EMT), as demonstrated by its induction of E‑cadherin and suppression of vimentin and N‑cadherin at the mRNA and protein levels. Furthermore, oldhamianoside II treatment upregulated Wnt antagonist expression and promoted the proteasome‑mediated degradation of β‑catenin to inhibit the activity of β‑catenin signaling. In summary, the present study revealed that oldhamianoside II exerts its antitumor effects via the regulation of EMT and β‑catenin function, and further supports its potential for use in clinical treatment.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP and Zattoni F: European Association of Urology: EAU guidelines on prostate cancer. Eur Urol. 53:68–80. 2008. View Article : Google Scholar : PubMed/NCBI
3	Gonzalez DM and Medici D: Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 7:ra82014. View Article : Google Scholar : PubMed/NCBI
4	Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S and Sarkar FH: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI
5	Nauseef JT and Henry MD: Epithelial-to-mesenchymal transition in prostate cancer: Paradigm or puzzle? Nat Rev Urol. 8:428–439. 2011. View Article : Google Scholar : PubMed/NCBI
6	Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 1653:1–24. 2003.PubMed/NCBI
7	Rabbani SA, Arakelian A and Farookhi R: LRP5 knockdown: Effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2:625–635. 2013.PubMed/NCBI
8	Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM and Keller ET: Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res. 68:5785–5794. 2008. View Article : Google Scholar : PubMed/NCBI
9	Sun JY, Zhong Y, Yin JT, Liu L, Wang B and Zuo CX: Isolation and structure identification of triterpenoids from Gypsophila oldhamiana. Chin Trad Herbal Drugs. 36:644–646. 2005.
10	Wang FL, Sun JY, Wang Y, Mu YL, Liang YJ, Chong ZZ, Qin SH and Yao QQ: Oldhamianoside II, a new triterpenoidsaponin, prevents tumor growth via inducing cell apoptosis and inhibiting angiogenesis. Oncol Res. 20:369–376. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang L, Zhang J, Yang X, Chang YW, Qi M, Zhou Z, Zhang J and Han B: SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial-mesenchymal transition in vitro. Prostate Cancer Prostatic Dis. 16:301–307. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wang L, Zheng Y, Xu H, Yan X and Chang X: Investigate pathogenic mechanism of TXNDC5 in rheumatoid arthritis. PLoS One. 8:e533012013. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Wang L, Li Y, Yang X, Yuan H, Li X, Qi M, Chang YW, Wang C, Fu W, Yang M, et al: ERG-SOX4 interaction promotes epithelial-mesenchymal transition in prostate cancer cells. Prostate. 74:647–658. 2014. View Article : Google Scholar : PubMed/NCBI
15	Smith BN and Odero-Marah VA: The role of Snail in prostate cancer. Cell Adh Migr. 6:433–441. 2012. View Article : Google Scholar : PubMed/NCBI
16	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:29–26. 2009. View Article : Google Scholar
17	Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
18	Fischer JA: Deubiquitinating enzymes: Their roles in development, differentiation, and disease. Int Rev Cytol. 229:43–72. 2003. View Article : Google Scholar : PubMed/NCBI
19	Arend RC, Londoño-Joshi AI, Straughn JM Jr and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
20	Koch A, Waha A, Hartmann W, Hrychyk A, Schüller U, Waha A, Wharton KA Jr, Fuchs SY, von Schweinitz D and Pietsch T: Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res. 11:4295–4304. 2005. View Article : Google Scholar : PubMed/NCBI
21	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
22	Bullions LC and Levine AJ: The role of beta-cateninin cell adhesion, signal transduction, and cancer. Curr Opin Oncol. 10:81–87. 1998. View Article : Google Scholar : PubMed/NCBI
23	Mulholland DJ, Dedhar S, Coetzee GA and Nelson CC: Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev. 26:898–915. 2005. View Article : Google Scholar : PubMed/NCBI
24	Sundram V, Chauhan SC, Ebeling M and Jaggi M: Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One. 7:e353682012. View Article : Google Scholar : PubMed/NCBI
25	Yokoyama NN, Shao S, Hoang BH, Mercola D and Zi X: Wnt signaling in castration-resistant prostate cancer: Implications for therapy. Am J Clin Exp Urol. 15:27–44. 2014.
26	Park JH, Kwon HY, Sohn EJ, Kim KA, Kim B, Jeong SJ, Song JH, Koo JS and Kim SH: Inhibition of Wnt/β-catenin signaling mediates ursolic acid-induced apoptosis in PC-3 prostate cancer cells. Pharmacol Rep. 65:1366–1374. 2013. View Article : Google Scholar : PubMed/NCBI
27	Robinson DR, Zylstra CR and Williams BO: Wnt signaling and prostate cancer. Curr Drug Targets. 9:571–580. 2008. View Article : Google Scholar : PubMed/NCBI
28	Kypta RM and Waxman J: Wnt/β-catenin signaling in prostate cancer. Nat Rev Urol. 9:418–428. 2012. View Article : Google Scholar : PubMed/NCBI
29	Kagey MH and He X: Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. Br J Pharmacol. 174:4637–4650. 2017. View Article : Google Scholar : PubMed/NCBI
30	Cheng AS, Lau SS, Chen Y, Kondo Y, Li MS, Feng H, Ching AK, Cheung KF, Wong HK, Tong JH, et al: EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res. 71:4028–4039. 2011. View Article : Google Scholar : PubMed/NCBI